Echocardiography in Pulmonary Arterial Hypertension: Is It Time to Reconsider Its Prognostic Utility?
Ioannis T FarmakisEftychia DemeroutiPanagiotis KaryofyllisGeorge KaratasakisStratinaki MariaDimitrios TsiaprasGeorge AthanassopoulosVassilios VoudrisGeorge GiannakoulasPublished in: Journal of clinical medicine (2021)
Pulmonary arterial hypertension (PAH) is characterized by an insult in the pulmonary vasculature, with subsequent right ventricular (RV) adaptation to the increased afterload that ultimately leads to RV failure. The awareness of the importance of RV function in PAH has increased considerably because right heart failure is the predominant cause of death in PAH patients. Given its wide availability and reduced cost, echocardiography is of paramount importance in the evaluation of the right heart in PAH. Several echocardiographic parameters have been shown to have prognostic implications in PAH; however, the role of echocardiography in the risk assessment of the PAH patient is limited under the current guidelines. This review discusses the echocardiographic evaluation of the RV in PAH and during therapy, and its prognostic implications, as well as the potential significant role of repeated echocardiographic assessment in the follow-up of patients with PAH.
Keyphrases
- pulmonary hypertension
- pulmonary arterial hypertension
- left ventricular
- polycyclic aromatic hydrocarbons
- mycobacterium tuberculosis
- pulmonary artery
- heart failure
- ejection fraction
- risk assessment
- computed tomography
- mitral valve
- end stage renal disease
- chronic kidney disease
- newly diagnosed
- stem cells
- atrial fibrillation
- human health
- cardiac resynchronization therapy
- prognostic factors
- mesenchymal stem cells
- heavy metals
- climate change